These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9598420)

  • 21. A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent.
    Shkedy Z; Molenberghs G; Van Craenendonck H; Steckler T; Bijnens L
    J Biopharm Stat; 2005; 15(2):225-39. PubMed ID: 15796291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian versus frequentist hypotheses testing in clinical trials with dichotomous and countable outcomes.
    Zaslavsky BG
    J Biopharm Stat; 2010 Sep; 20(5):985-97. PubMed ID: 20721786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
    Holt MM; Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with reviewing Bayesian medical device trials.
    Pennello G; Thompson L
    J Biopharm Stat; 2008; 18(1):81-115. PubMed ID: 18161543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesians in clinical trials: asleep at the switch.
    Moyé LA
    Stat Med; 2008 Feb; 27(4):469-82; discussion 483-9. PubMed ID: 17573687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal crossover designs for logistic regression models in pharmacodynamics.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-period crossover designs for two treatments.
    Ebbutt AF
    Biometrics; 1984 Mar; 40(1):219-24. PubMed ID: 6733230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian approach to the statistical analysis of device preference studies.
    Fu H; Qu Y; Zhu B; Huster W
    Pharm Stat; 2012; 11(2):149-56. PubMed ID: 22374584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Bayesian analysis of the two-period crossover design for clinical trials.
    Grieve AP
    Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline observation carry forward: reasoning, properties, and practical issues.
    Shao J; Jordan DC; Pritchett YL
    J Biopharm Stat; 2009 Jul; 19(4):672-84. PubMed ID: 20183433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A confidence interval for the ratio of treatment variances in a two-by-two crossover study.
    Bristol DR
    J Biopharm Stat; 1991; 1(2):237-45. PubMed ID: 1844699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Roaming through methodology. XXXVI. Likelihood ratios and Bayes' rule].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2421-4. PubMed ID: 11776667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of relative improvement due to weights within generalized estimating equations framework for incomplete clinical trials data.
    Demirtas H
    J Biopharm Stat; 2004 Nov; 14(4):1085-98. PubMed ID: 15587981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.